Background {#Sec1}
==========

Trans-catheter aortic valve replacement (TAVR), previously reserved for surgically high-risk patients with symptomatic aortic stenosis (AS), is now being utilized in a wider range of patients \[[@CR1], [@CR2]\]. Patients treated with TAVR have shown significant alleviation of symptoms and improved functional status \[[@CR3], [@CR4]\].

Diabetes mellitus (DM) and AS are both prevalent in the elderly population, and symptomatic AS has been found to be associated with DM \[[@CR5]\]. Following cardiac surgery, patients with DM have been shown to suffer higher rates of renal dysfunction, need for blood transfusions and lung complications. Furthermore, DM patients undergoing TAVR have been shown to have less complications than DM patients undergoing surgical aortic valve replacement (SAVR) \[[@CR6]\], and while mortality rates in patients undergoing TAVR have been shown to be equivalent \[[@CR7]\] or reduced \[[@CR8]\] compared with patients treated with SAVR, little is known about the impact of DM on the clinical outcomes of patients undergoing TAVR compared with the non-DM population. The aim of the current study was to investigate the clinical outcomes and complication rates among DM patients undergoing TAVR.

Methods {#Sec2}
=======

The study included 443 consecutive patients undergoing TAVR at the Sheba Medical Center between January 2008 and December 2014, of which 158 (36 %) had DM. We analyzed separately DM patients treated with insulin (IDDM) (44 \[28 %\]) and those treated either by diet or oral anti-diabetic agents (114 \[72 %\]). Candidates for TAVI were evaluated separately by an interventional cardiologist and by a cardiac surgeon. Cases were then discussed by the heart team which convenes on a weekly basis. Final decision to advise TAVR vs. SAVR was made by the heart team based on suitability for TAVI and surgical risk.

Baseline clinical data and chronic medication use were obtained from patients' electronic records. Patients with impaired renal function (creatinine \>1.2 mg/dl) received peri-procedural balanced intravenous volume expansion with isotonic sodium chloride \[[@CR9]\]. Peri-procedural complications were prospectively recorded according to the Valve Academic Research Consortium (VARC)-2 criteria. Mortality rates were ascertained with the Israeli Ministry of Interior mortality database through January 2015.

The study was approved by the local institutional review board (clinicaltrial.gov: SHEBA-13-0685-IB-CTIL).

Definitions and outcome measures {#Sec3}
--------------------------------

Patients were considered to have DM if they fulfilled at least one of the followings: (1) HbA1c \>6.5 % at admission, (2) a random plasma glucose level higher than 200 mg/dl in the presence of symptoms, (3) use of glucose lowering medications. All DM patients had type 2 DM. Renal dysfunction was defined as a serum creatinine level greater than 1.4 mg %.

The primary outcome of the current study was all cause mortality during a follow-up period of 2 years. Median follow-up time for the entire study population was 599 days. Secondary outcomes were defined as any VARC-2 defined peri-procedural complication.

Statistical analysis {#Sec4}
--------------------

Continuous data were compared with Student's t-test and one-way ANOVA. Categorical data were compared with the use of Pearson Chi square test.

Kaplan--Meier survival analysis was used to descriptively show the association between DM and subsequent mortality. Multivariate cox regression adjusted for age, gender, coronary artery disease, DM, AKI3, hypertension, chronic renal failure and peripheral vascular disease was performed in order to find risk factors for mortality. Statistical significance was accepted for a two-sided p \< 0.05. The statistical analyses were performed with IBM SPSS version 20.0 (Chicago, IL, USA).

Results {#Sec5}
=======

Of 443 patients included in the study 158 (36 %) had DM. These patients were compared with the 285 (64 %) patients without DM. Of the 158 diabetic patients 44 (28 %) were treated with insulin, while the others were treated either orally or by diet. Baseline clinical and laboratory characteristic by DM status are presented in Table [1](#Tab1){ref-type="table"}. Notably, DM subjects were on average 2 years younger than non-diabetic patients and had a greater incidence of dyslipidemia. Subjects with IDDM had significantly greater incidence of baseline renal dysfunction. However, no other major differences in baseline characteristics were noted between groups, including STS score, EUROSCORE, NYHA class, or presence of coronary artery disease.Table 1Baseline characteristicsNon-diabetic (N = 285)Diabetic (N = 158)P-valueNIDDM (N = 114)IDDM (N = 44)Age81.8 ± 7.579.8 ± 7.579.4 ± 7.70.016Male128 (46)53 (46)23 (52)0.71Hemoglobin11.5 (1.4)11.6 (1.4)12.6 (2.2)0.18Glucose91 (13)97 (21)95 (34)0.21Renal dysfunction46 (17)21 (20)23 (59)\<0.001Hypertension232 (84)103 (94)34 (83)0.032Dyslipidemia199 (72)90 (83)34 (85)0.036Coronary artery disease124 (46)48 (45)24 (60)0.22CHF-NYHA class III--IV165 (58)62 (54)23 (52)0.64Atrial fibrillation/flutter66 (27)29 (28)13 (33)0.71Peripheral vascular disease33 (12)13 (12)6 (15)0.85Current smoker11 (4)2 (2)2 (5)0.53COPD41 (15)19 (18)11 (28)0.13s/p CABG57 (21)22 (21)10 (26)0.8s/p PCI73 (27)30 (29)14 (36)0.55Pacemaker21 (8)7 (7)2 (5)0.79STS mortality5.3 ± 3.75.2 ± 2.97.6 ± 5.60.21EUROSCORE 24.9 ± 5.14.7 ± 5.39.1 ± 8.70.16HbA1c5.7 ± 0.436.8 ± 1.007.9 ± 1.47\<0.001All values are expressed as mean ± SD or N (%)*NIDDM* non-insulin dependent diabetes mellitus, *IDDM* insulin dependent diabetes mellitus, *CHF* congestive heart failure, *NYHA* New York Heart Association, *COPD* chronic obstructive lung disease, *CABG* coronary artery bypass surgery, *PCI* percutaneous coronary intervention, *STS* Society of Thoracic Surgeons

Procedural characteristics are summarized in Table [2](#Tab2){ref-type="table"}. In most patients TAVR was performed via the trans-femoral approach (76 %) using conscious sedation (63 %). There were no differences between groups regarding the vascular approach, type of anesthesia, valve type or valve size used.Table 2Procedural characteristics of TAVR patientsNon-diabetic (N = 285)Diabetic (N = 158)P-valueNIDDM (N = 114)IDDM (N = 44)Approach Trans-femoral209 (76)86 (79)31 (74)0.53 Trans-apical49 (18)19 (17)9 (21) Other17 (6)3 (3)2 (5)Anesthesia General89 (39)34 (34)12 (36)0.55 Conscious sedation140 (61)66 (66)21 (61)Valve type SAPIEN XT109 (41)48 (45)18 (45)0.35 CoreValve159 (58)55 (51)20 (50) Other5 (1)2 (2)0 (0)Valve size 23 mm52 (20)19 (18)9 (24)0.77 25 mm0 (0)1 (1)0 (0) 26 mm106 (41)45 (44)13 (35) 29 mm93 (36)34 (33)13 (35) 31 mm6 (2)4 (4)2 (5) Valve-in-valve25 (9)12 (11)8 (20)0.11 Procedural success262 (98)103 (97)38 (100)0.59 Pre procedural EF55 ± 1256 ± 1254 ± 120.48 Pre-procedural moderate to severe MR74 (26)26 (23)10 (23)0.76 Post-procedural moderate to severe AR37 (13)14 (12)2 (5)0.27All values expressed as N (%)*NIDDM* non-insulin dependent diabetes mellitus, *IDDM* insulin dependent diabetes mellitus

Diabetic patients demonstrated similar complication rates compared with non-diabetic patients (Table [3](#Tab3){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}), except for acute kidney injury (AKI) grade 3, which was more common in the IDDM group \[1 (0.4 %) vs. 3 (3 %) and 2 (4 %), for non-diabetic, NIDDM, and IDDM respectively, p = 0.032\]. No other significant differences were noted between groups.Table 3Cardiac complicationsComplicationNon-diabetic (N = 285)Diabetic (N = 158)P-valueNIDDM (N = 114)IDDM (N = 44)30-days mortality12 (4.2)3 (2.6)2 (4.5)0.736-months mortality28 (9.8)5 (4.4)3 (6.8)0.181-year mortality39 (13.7)11 (9.6)4 (9.1)0.43Conversion to open surgery5 (2)0 (0)0 (0)0.24Unplanned cardiopulmonary bypass3 (1)0 (0)0 (0)0.43Coronary obstruction1 (0.4)1 (0.9)0 (0)0.7Cardiac tamponade8 (3)4 (4)1(2)0.91Valve malpositioning11 (4)7 (6)1 (2)0.5Valve migration11 (4)5 (4)1 (2)0.83Peri-procedural MI (≤72 h post procedure)9 (3)1(1)1 (2)0.41Spontaneous MI (≤72 h post procedure)3 (1)0 (0)1 (2)0.36Transient atrio-ventricular block21 (9)9 (9)3 (7)0.96Permanent atrio-ventricular block41 (17)18 (18)5 (12)0.72Permanent pacemaker implantation55 (22)24 (23)8 (19)0.86New LBBB78 (32)30 (29)8 (19)0.27New RBBB3 (1)1 (1)0 (0)0.77New onset AF27 (11)17 (16)3 (7)0.22AF episode in patient with history of AF13 (5)7 (7)3 (7)0.78Heart failure post-procedure23 (9)12 (12)7 (17)0.33All values expressed as N (%)*NIDDM* non-insulin dependent diabetes mellitus, *IDDM* insulin dependent diabetes mellitus, *MI* myocardial infarction, *LBBB* left bundle branch block, *RBBB* right bundle branch block, *AF* atrial fibrillationFig. 1Systemic complication rates. The figure shows the systemic complication rates (in percentage) according to diabetic status

The primary study outcome occurred in 108 (24.4 %) subjects. Kaplan--Meier survival analysis (Fig. [2](#Fig2){ref-type="fig"}) showed that the cumulative probability for mortality through 2 years of follow-up was not different between the groups (p-value Log rank = 0.439), although there was a trend towards higher mortality among patients with IDDM.Fig. 2Kaplan--Meier analysis for 2 years survival. The Kaplan--Meier analysis was used to compare the probability of 2 years survival according to diabetic status. P value (Log rank) = 0.439

Multivariate cox regression adjusted for age, gender, coronary artery disease, DM, AKI3, hypertension, chronic renal failure and peripheral vascular disease found that AKI3 \[HR = 7.35, 95 % CI 2.16--25.07, p = 0.001\] and peripheral vascular disease \[HR = 1.95, 95 % CI 1.12--3.39, p = 0.019\] were associated with increased risk of 2-year mortality. Female gender was found to be a protective factor \[HR = 0.47, 95 % CI 0.28--0.8, p = 0.005\] and DM was not associated with increased risk (Table [4](#Tab4){ref-type="table"}).Table 4Multivariate cox regression analysis for 2-year mortalityFactorHR95 % confidence intervalP valueAcute kidney injury 37.352.15--25.070.001Peripheral vascular disease1.951.12--3.390.019Chronic renal failure1.590.96--2.620.07Diabetes mellitus0.830.49--1.400.48Female gender0.470.28--0.800.005Analysis was further adjusted for age, coronary artery disease and hypertension

We performed two additional sub-group analyses: first we analyzed outcomes of diabetic patients based on their HbA1C levels. Documented HbA1C levels during hospitalization were available in 105 patients with DM. Outcomes of well-controlled diabetic patients with HbA1C levels below 7 % were equivalent to diabetic patients with HbA1C levels equal to or above 7 % (Additional file [1](#MOESM1){ref-type="media"}: Table S1). While numerically higher 1 year mortality rates were noted among DM patients with HbA1c levels above 7 % compared with those below 7 % \[2 (4 %) vs 5 (9 %), p = 0.23\], this finding did not reach statistical significance, probably due to the relatively small group sample.

Discussion {#Sec6}
==========

The major finding of our study is that DM patients undergoing TAVR seem to have favorable outcomes with similar short and mid-term mortality rates compared with non-DM patients. Patients with IDDM in our study had greater incidence of renal insufficiency at baseline and both DM groups suffered from increased rate of AKI after the procedure, however other peri-procedural complications occurred equally among DM and non-DM patients.

Up to 40 % of older individuals have DM \[[@CR10]\]. Elderly DM patients have unique characteristics and suffer from higher cardiovascular disease rates compared to younger DM patients \[[@CR11]\]. However, limited data exists with respect to the effect of DM on mortality after TAVR. Our findings are supported by two previous studies: Minha et al. \[[@CR12]\] followed 499 patients who had TAVR and concluded that DM was not associated with poor outcome. However in this study patients were not divided according to treatment type (insulin vs. oral hypoglycemic agents). Conrotto et al. \[[@CR13]\] examined 511 patients undergoing TAVR, of whom 150 had DM, and also found no difference regarding the short and mid-term effect of DM on mortality rates in these patients. A number of studies suggest differential outcomes in DM patients: Tamburino et al. \[[@CR14]\], in a study of 663 patients after TAVR found a higher incidence of DM among those who died and argued that DM at baseline may be associated with increased mortality. However this study failed to compare baseline characteristics between DM and non-DM subjects and is inherently biased in that it examined characteristics of patients who died following the procedure. Similarly, Puls et al. \[[@CR15]\] reported poor outcome among 108 DM patients. However, in contrast to our series, most TAVR were performed by the transapical approach and their total mortality rates were much higher than those found in our cohort, suggesting that these patients had greater baseline risk.

While we failed to demonstrate statistically significant differences in mortality rates between IDDM and NIDDM patients, Kaplan--Meier analysis did suggest a trend towards worse outcomes among IDDM subjects. However, our sample size is inadequate to properly address mortality between groups.

Acute kidney injury rates were significantly higher among DM patients, especially the IDDM group. This finding is not surprising given the higher CRF rates at baseline. Previous studies have found CRF and AKI injury to be predictors for in-hospital mortality, 30 days mortality and 1 year mortality post-TAVR \[[@CR16]--[@CR19]\]. Our findings are similar to those mentioned above. However, and despite having higher rates of AKI, IDDM patients in our study did not demonstrate significantly higher mortality rates when compared with NIDDM patients or with non-diabetic patients. A possible explanation for this discrepancy may be the small number of IDDM or the relatively small number of events (AKI) in the population which failed to reach statistical significance.

Limitations {#Sec7}
-----------

This paper is based on a moderately sized cohort emanating from a single center. The limited number of enrolled patients does not allow assessment of specific outcome measures and sub-group analysis and avoids the potential for a propensity-matched evaluation or use of post hoc comparisons between the three groups due to high-risk for type II errors. Larger cohorts are necessary to further assess the prognostic impact of diabetes mellitus on outcome after TAVR.

Conclusions {#Sec8}
===========

Diabetic patients seem to have favorable short- and mid-term outcomes following TAVR which are similar to patients without DM. Insulin treated DM patients may have greater incidence of AKI, and appropriate peri-procedural strategies should be employed to minimize this risk in these patients.
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